Nigeria Ebola response intensifies after an imported Bundibugyo virus case, renewing concerns about surveillance, treatment and public health preparedness.

When Dr Ameyo Stella Adadevoh insisted on isolating Liberian-American patient Patrick Sawyer at First Consultants Medical Centre in Lagos in July 2014, she faced a medical emergency that would become one of the defining moments in Nigeria’s public health history.

Also read:10 phones with the biggest batteries in Nigeria

Her decision helped prevent a potentially devastating Ebola outbreak, but the physician contracted the virus and died on 19 August 2014.

Nigeria recorded 20 Ebola cases and eight deaths during that outbreak before the World Health Organisation (WHO) declared the country free of Ebola transmission on 20 October 2014.

More than 12 years later, Ebola has again placed Nigeria’s public health preparedness under scrutiny.

On 20 October 2026, Nigeria confirmed an imported case of Bundibugyo virus disease, a form of Ebola, in a 42-year-old woman who had travelled from Uganda and received treatment at a private hospital in Abuja.

The confirmation renewed concerns about the ability of infectious diseases to cross international borders and the readiness of healthcare systems to identify and contain emerging outbreaks.

However, the latest situation offers some reassurance. According to the Nigeria Centre for Disease Control and Prevention (NCDC), the patient was medically evacuated to Switzerland on 26 October following arrangements between the relevant authorities.

As of 29 October, Nigeria had recorded one confirmed case, no deaths and no confirmed secondary infections. The NCDC had identified 62 contacts who remained under monitoring.

A suspected case reported in Enugu had also tested negative.

The figures are important because the confirmation of an imported infection does not automatically mean that an outbreak has developed within the country.

The challenge for health authorities is to ensure that the virus does not spread beyond the original case through delayed detection, inadequate infection prevention or missed contacts.

Adadevoh’s experience remains a powerful reminder that the first opportunity to contain an infectious disease often rests with the decisions made in a hospital consultation room.

The circumstances surrounding the latest case are different, but the underlying public health lesson remains relevant: early recognition, prompt reporting and coordinated action can make a decisive difference.

Ebola has not disappeared. Its continued circulation in animal populations, recurring outbreaks and ability to spread through human contact mean that countries must maintain surveillance even when they have gone years without a confirmed case.

For Dr Rotimi Adesanya, a family physician and public health expert, Ebola remains particularly dangerous because of its ability to cause severe illness and affect multiple organs.

“Ebola Virus Disease is one of the most dangerous infectious diseases known to mankind because of its ability to overwhelm the body’s immune system and cause severe damage to multiple vital organs within a relatively short period,” he said.

The early symptoms include fever, headache, weakness, muscle and joint pain, sore throat and fatigue.

As the disease progresses, patients may develop vomiting, diarrhoea and abdominal pain. Severe cases can involve dehydration, shock and multiple organ failure.

One of the difficulties is that the initial symptoms can resemble malaria, typhoid and other common infections in Nigeria.

This makes a patient’s medical and travel history particularly important during clinical assessment, especially when there has been possible exposure to an area experiencing an Ebola outbreak.

Symptoms typically develop between two and 21 days after exposure.

Adesanya cautioned against the widespread assumption that visible bleeding must occur before Ebola can be suspected.

“Contrary to popular belief, not every Ebola patient experiences bleeding. In fact, severe dehydration, shock and multiple organ failure are among the major causes of death,” he explained.

The distinction matters because waiting for advanced symptoms before considering Ebola could delay isolation, testing and other necessary public health interventions.

“Early diagnosis saves two lives. The life of the infected patient and potentially the lives of others who might otherwise become infected,” Adesanya said.

According to the NCDC, Ebola spreads through direct contact with the blood or other bodily fluids of an infected person, a person who has died from the disease, infected animals or contaminated materials.

It does not spread through the air in the same way as measles.

The absence of airborne transmission, however, does not make the disease less serious. Close contact with infectious bodily fluids can create significant exposure risks, particularly in healthcare settings where protective measures are inadequate.

Containing an outbreak does not mean the virus has been eradicated.

Ebola is a zoonotic disease, meaning it can spread from animals to humans. Scientists believe certain species of fruit bats may serve as natural reservoirs for some Ebola viruses, although the precise ecological pathways remain incompletely understood.

Human infections can occur through contact with infected wildlife or their bodily fluids, particularly during hunting, handling, slaughtering and preparation of wild animals.

Chimpanzees, gorillas, monkeys and forest antelopes can also become infected. However, these animals are susceptible hosts and should not automatically be described as natural reservoirs.

Environmental changes may increase opportunities for transmission. Deforestation, agricultural expansion, mining and human encroachment into forest habitats can bring people into closer contact with wildlife.

According to Adesanya, the challenge extends beyond identifying the virus itself.

Weak surveillance systems, inadequate laboratory facilities, poverty, population displacement and distrust of public health authorities can all complicate outbreak control.

Communities without reliable healthcare services may struggle to access early diagnosis, while conflict and insecurity can prevent health workers from reaching affected populations.

Adesanya argued that preventing future outbreaks requires a comprehensive One Health approach, bringing human health, animal health and environmental protection together.

Such an approach would involve public health authorities working with veterinary services, wildlife specialists, environmental agencies and communities to identify potential risks before infections spread into human populations.

The importance of this collaboration becomes clearer when considering the role of bush meat in parts of Africa.

Hunting and selling wild animals provide food and income for some communities. However, exposure to potentially infected animals can occur during hunting, transportation, skinning and butchering.

The risk is not limited to eating contaminated meat. Contact between infectious animal blood and broken skin or the eyes, nose and mouth can also lead to infection.

Public health education must therefore offer practical guidance without stigmatising communities or disregarding their economic circumstances.

Reporting unusual animal deaths, improving wildlife surveillance and strengthening cooperation with hunters and local health workers can help identify potential spillover events.

The wider lesson is that Ebola prevention cannot begin only after a patient arrives at a hospital.

The current outbreak also highlights an important scientific distinction that is sometimes overlooked in public discussions about Ebola.

Ebola disease is caused by different viruses within the Orthoebolavirus group. These include Ebola virus, Bundibugyo virus, Sudan virus and Taï Forest virus.

The virus confirmed in Nigeria belongs to the Bundibugyo species.

The ongoing outbreak was declared in the Democratic Republic of the Congo on 15 May 2026. It subsequently spread across several countries, with imported cases reported in Kenya and Nigeria.

According to the WHO’s 23 October situation report, the Democratic Republic of the Congo had recorded 9,704 confirmed cases and 4,687 deaths as of 20 October, across 66 health zones in eight provinces.

Kenya had recorded nine confirmed cases, including one death, by the same reporting date.

The eight additional Kenyan cases were linked to the first imported infection, illustrating how an infection crossing a border can generate further transmission if exposed contacts are not identified and monitored promptly.

Nigeria’s case was therefore part of a wider regional public health emergency rather than an isolated development without international context.

Ebola is not automatically a death sentence. Survival depends on several factors, including the virus species, the patient’s condition and access to appropriate medical care.

However, one important complication is that treatments developed for one Ebola species cannot automatically be assumed to work against another.

For Bundibugyo virus disease, there are currently no licensed vaccines or specifically approved antiviral treatments.

The WHO has identified promising candidate treatments, including the monoclonal antibodies MBP134 and Maftivimab, as well as the antiviral drug remdesivir.

However, these products require evaluation through properly designed clinical trials.

The Ervebo vaccine, which is licensed for protection against disease caused by the Ebola virus species, is not licensed for Bundibugyo virus disease.

The WHO has cautioned that evidence of its effectiveness against Bundibugyo virus in humans remains insufficient and recommends its use against this strain only within an appropriate research protocol.

For now, treatment of Bundibugyo virus disease focuses on supportive medical care.

This includes intravenous fluids, correction of electrolyte imbalances, maintaining blood pressure and oxygen levels, nutritional support and monitoring the functioning of vital organs.

Prompt treatment of complications can improve a patient’s chances of survival.

The absence of an approved virus-specific treatment or vaccine makes early detection, isolation and infection prevention particularly important.

Nigeria’s response to the October case has demonstrated the importance of maintaining disease surveillance even after a country has successfully contained an earlier outbreak.

The NCDC’s situation report of 29 October 2026 provides a clearer picture of the response.

The agency confirmed that 62 contacts linked to the imported case had been identified and categorised for monitoring.

It also reported that no new contacts had been identified in the preceding 24 hours and that no monitored contacts were showing symptoms.

Of the 18 samples tested, only the original patient’s sample had returned positive, while 17 were negative.

The NCDC further confirmed that the patient had been medically evacuated to Switzerland on 26 October, following a formal request from her country and approval from Nigerian authorities.

The agency said the response was being coordinated through an activated National Incident Management System, with contact tracing, laboratory surveillance and infection prevention measures continuing.

The University of Abuja Teaching Hospital was also assessed for its readiness to serve as an isolation and treatment centre.

These developments are encouraging, but they do not remove the need for sustained vigilance.

Contact monitoring must continue for the full prescribed observation period, and health authorities must remain prepared to investigate any suspected infection.

Healthcare workers also require adequate personal protective equipment, training, isolation facilities and safe referral arrangements.

Adadevoh’s death remains a reminder of the personal risks faced by medical professionals during outbreaks.

Her experience also demonstrates why infection prevention must be treated as a fundamental part of healthcare delivery rather than an emergency measure introduced only after a confirmed case.

International travel has become an important consideration in the management of infectious diseases.

An infected person may travel between countries before symptoms become apparent or before a diagnosis is established.

In the Nigerian case, the patient arrived in Abuja on 3 October after travelling from Uganda through Addis Ababa.

Symptoms began on 7 October, and she was admitted to a private health facility on 11 October. The NCDC was notified on 19 October, and laboratory confirmation followed on 20 October.

The timeline demonstrates why travel history is important when assessing patients with symptoms compatible with Ebola.

However, travel itself should not be treated as evidence that someone is infected.

The WHO has emphasised the importance of coordinated surveillance, screening at relevant points of entry and rapid information-sharing between countries.

It has also advised against general travel and trade restrictions on affected countries, noting that such measures are not supported by the available scientific evidence.

Effective contact tracing and timely communication remain more useful tools for identifying potential exposures and preventing further transmission.

Nigeria’s experience in 2014 demonstrated that professional judgement, rapid public health coordination and community cooperation can prevent an infectious disease from becoming a national catastrophe.

The country’s successful containment of that outbreak was achieved through the combined efforts of healthcare workers, government agencies, international partners and affected communities.

Yet, more than a decade later, the latest imported case shows that previous success cannot replace continued preparedness.

The current situation is different from the 2014 outbreak. As of 29 October 2026, Nigeria had recorded one confirmed case, no deaths and no confirmed secondary infections. Those figures should provide measured reassurance rather than grounds for complacency.

The immediate priority is to complete contact monitoring, maintain effective surveillance and ensure that healthcare facilities can recognise and safely manage suspected infections.

Beyond the immediate response, Nigeria must continue investing in laboratory capacity, emergency treatment facilities, healthcare worker protection and cooperation between human and animal health authorities.

For communities, understanding how Ebola spreads, recognising possible exposure and reporting suspected cases promptly remain essential.

Dr Adadevoh’s legacy is not simply a story of sacrifice. It is also a reminder of the value of vigilance, professional responsibility and timely action.

Ebola may continue to emerge from its natural environment and cross international borders, but its impact on human populations can be reduced through science, preparedness and public trust.

Also read:10 phones with the biggest batteries in Nigeria

Nigeria has confronted the disease before and demonstrated that containment is possible. The task now is to ensure that the lessons learned in Lagos in 2014 remain firmly embedded in the country’s healthcare system in 2026 and beyond.